We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns?
Read MoreHide Full Article
Key Takeaways
Teleflex raised 2026 adjusted EPS guidance to $6.90-$7.20 after the OEM sale.
Teleflex's OEM proceeds helped cut pro forma net leverage to 1.9X from 2.8X at Q2 end.
Teleflex's revenue-growth guidance fell to 3.5%-4.5% as margins faced tariff and acquisition pressures.
Teleflex Incorporated (TFX - Free Report) has moved a major piece of its portfolio reset from plan to execution. The August 2026 sale of its OEM business brought in $1.5 billion in cash, giving the company immediate capacity to reduce debt and continue returning capital to shareholders.
The financial effect is already visible. Teleflex raised its 2026 adjusted earnings outlook even as it cut its underlying revenue-growth forecast, shifting the near-term investment case toward capital allocation and balance-sheet improvement rather than faster operating growth.
How Teleflex's OEM Sale Strengthens the Balance Sheet
Teleflex estimates after-tax proceeds from the OEM sale at about $1.25 billion. It used the proceeds primarily to repay roughly $700 million of Term Loan A-2 debt tied to the Vascular Intervention acquisition and to replenish funds used for second-quarter share repurchases.
That action reduced pro forma net leverage to about 1.9X from 2.8X at second-quarter end. The lower debt load should improve financial flexibility and help reduce interest expense as Teleflex continues its broader plan to cut debt by about $800 million using strategic-divestiture proceeds.
Why TFX Raised Its 2026 EPS Guidance
Teleflex lifted 2026 adjusted earnings guidance to $6.90-$7.20 from $6.25-$6.55. The new range reflects second-quarter results, the benefit of second-quarter share repurchases and lower expected net interest expense.
Image Source: Zacks Investment Research
The company repurchased about 1.9 million shares for $250 million during the second quarter and planned a $250 million accelerated share repurchase effective Aug. 7. The raised EPS range does not include the anticipated benefit from that accelerated repurchase or other expected second-half buybacks, leaving additional capital deployment outside the current guidance.
What Teleflex Still Must Complete in 2026
The Acute Care and Interventional Urology divestiture remains unfinished. Teleflex expects the transaction to close in the fourth quarter of 2026, subject to regulatory approval, after the Federal Trade Commission issued a second request in March.
Separation costs totaled $29 million in the second quarter and $59.2 million in the first half. Teleflex expects transition and manufacturing service agreements tied to the pending sale to help offset stranded costs on an annualized basis, while a restructuring program targets about $50 million of annual pretax savings by mid-2028.
How TFX's Margin Pressure Complicates the Upside
Capital-allocation benefits are arriving while core profitability remains under pressure. Second-quarter adjusted gross margin fell 280 basis points to 61.7%, reflecting tariffs and the lower gross-margin profile of the acquired Vascular Intervention business. Adjusted operating margin declined 520 basis points to 19.6% as acquisition-related operating costs and higher R&D spending added pressure.
Teleflex expects adjusted operating margin of about 19% for 2026. In vascular access, Becton, Dickinson and Company (BDX - Free Report) remains a relevant peer after launching its CentroVena One central venous catheter insertion system in April 2026. Boston Scientific Corporation (BSX - Free Report) provides another comparison in interventional markets through its interventional cardiology and peripheral interventions portfolios.
Teleflex's Signals Support a Balanced View
The OEM sale improves the balance sheet and supports a higher earnings outlook, but 2026 remains a transition year. Teleflex also lowered pro forma adjusted constant currency revenue-growth guidance to 3.5%-4.5% from 4.5%-5.5%, underscoring that capital-allocation benefits are emerging faster than a clean acceleration in operating growth.
Image Source: Zacks Investment Research
TFX currently carries a Zacks Rank #2 (Buy). Its Value Score of B, Momentum Score of B and VGM Score of B add favorable style characteristics to that short-term earnings-revision signal, while its Growth Score of C points to a more moderate growth profile. That mix supports a constructive but measured view as the remaining divestiture, integration work and margin recovery progress.
View the Zacks #1 Rank List
Image: Bigstock
Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns?
Key Takeaways
Teleflex Incorporated (TFX - Free Report) has moved a major piece of its portfolio reset from plan to execution. The August 2026 sale of its OEM business brought in $1.5 billion in cash, giving the company immediate capacity to reduce debt and continue returning capital to shareholders.
The financial effect is already visible. Teleflex raised its 2026 adjusted earnings outlook even as it cut its underlying revenue-growth forecast, shifting the near-term investment case toward capital allocation and balance-sheet improvement rather than faster operating growth.
How Teleflex's OEM Sale Strengthens the Balance Sheet
Teleflex estimates after-tax proceeds from the OEM sale at about $1.25 billion. It used the proceeds primarily to repay roughly $700 million of Term Loan A-2 debt tied to the Vascular Intervention acquisition and to replenish funds used for second-quarter share repurchases.
That action reduced pro forma net leverage to about 1.9X from 2.8X at second-quarter end. The lower debt load should improve financial flexibility and help reduce interest expense as Teleflex continues its broader plan to cut debt by about $800 million using strategic-divestiture proceeds.
Why TFX Raised Its 2026 EPS Guidance
Teleflex lifted 2026 adjusted earnings guidance to $6.90-$7.20 from $6.25-$6.55. The new range reflects second-quarter results, the benefit of second-quarter share repurchases and lower expected net interest expense.
Image Source: Zacks Investment Research
The company repurchased about 1.9 million shares for $250 million during the second quarter and planned a $250 million accelerated share repurchase effective Aug. 7. The raised EPS range does not include the anticipated benefit from that accelerated repurchase or other expected second-half buybacks, leaving additional capital deployment outside the current guidance.
What Teleflex Still Must Complete in 2026
The Acute Care and Interventional Urology divestiture remains unfinished. Teleflex expects the transaction to close in the fourth quarter of 2026, subject to regulatory approval, after the Federal Trade Commission issued a second request in March.
Separation costs totaled $29 million in the second quarter and $59.2 million in the first half. Teleflex expects transition and manufacturing service agreements tied to the pending sale to help offset stranded costs on an annualized basis, while a restructuring program targets about $50 million of annual pretax savings by mid-2028.
How TFX's Margin Pressure Complicates the Upside
Capital-allocation benefits are arriving while core profitability remains under pressure. Second-quarter adjusted gross margin fell 280 basis points to 61.7%, reflecting tariffs and the lower gross-margin profile of the acquired Vascular Intervention business. Adjusted operating margin declined 520 basis points to 19.6% as acquisition-related operating costs and higher R&D spending added pressure.
Teleflex expects adjusted operating margin of about 19% for 2026. In vascular access, Becton, Dickinson and Company (BDX - Free Report) remains a relevant peer after launching its CentroVena One central venous catheter insertion system in April 2026. Boston Scientific Corporation (BSX - Free Report) provides another comparison in interventional markets through its interventional cardiology and peripheral interventions portfolios.
Teleflex's Signals Support a Balanced View
The OEM sale improves the balance sheet and supports a higher earnings outlook, but 2026 remains a transition year. Teleflex also lowered pro forma adjusted constant currency revenue-growth guidance to 3.5%-4.5% from 4.5%-5.5%, underscoring that capital-allocation benefits are emerging faster than a clean acceleration in operating growth.
Image Source: Zacks Investment Research
TFX currently carries a Zacks Rank #2 (Buy). Its Value Score of B, Momentum Score of B and VGM Score of B add favorable style characteristics to that short-term earnings-revision signal, while its Growth Score of C points to a more moderate growth profile. That mix supports a constructive but measured view as the remaining divestiture, integration work and margin recovery progress.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.